These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23558905)

  • 21. Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402.
    Azuma T; Tobinai K; Takeyama K; Shibata T; Hidaka M; Kurosawa M; Kasai M; Chou T; Fukushima N; Mukai K; Tsukasaki K; Shimoyama M;
    Jpn J Clin Oncol; 2012 May; 42(5):394-404. PubMed ID: 22422899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study.
    Takeuchi J; Kyo T; Naito K; Sao H; Takahashi M; Miyawaki S; Kuriyama K; Ohtake S; Yagasaki F; Murakami H; Asou N; Ino T; Okamoto T; Usui N; Nishimura M; Shinagawa K; Fukushima T; Taguchi H; Morii T; Mizuta S; Akiyama H; Nakamura Y; Ohshima T; Ohno R
    Leukemia; 2002 Jul; 16(7):1259-66. PubMed ID: 12094249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
    Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
    Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
    Pautas C; Merabet F; Thomas X; Raffoux E; Gardin C; Corm S; Bourhis JH; Reman O; Turlure P; Contentin N; de Revel T; Rousselot P; Preudhomme C; Bordessoule D; Fenaux P; Terré C; Michallet M; Dombret H; Chevret S; Castaigne S
    J Clin Oncol; 2010 Feb; 28(5):808-14. PubMed ID: 20048183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A regimen of DATV in the treatment of acute nonlymphocytic leukemia with high complete remission rate].
    Lou FD; Zhou Q; Meng FY
    Zhonghua Nei Ke Za Zhi; 1992 Mar; 31(3):146-8, 187. PubMed ID: 1395925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
    Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
    Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.
    Storring JM; Minden MD; Kao S; Gupta V; Schuh AC; Schimmer AD; Yee KW; Kamel-Reid S; Chang H; Lipton JH; Messner HA; Xu W; Brandwein JM
    Br J Haematol; 2009 Jun; 146(1):76-85. PubMed ID: 19438471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of acute lymphoblastic leukemia in adults with seven-drug induction therapy and intensive consolidation with or without autologous stem cell transplantation followed by maintenance therapy. Experience of a single center].
    Doubek M; Mayer J; Korístek Z; Protivánková M; Brychtová Y; Oborilová A; Král Z; Klabusay M; Tomíska M; Buchtová I; Vorlícek J
    Cas Lek Cesk; 2002 Mar; 141(4):122-6. PubMed ID: 12046256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma.
    Burkhardt B; Woessmann W; Zimmermann M; Kontny U; Vormoor J; Doerffel W; Mann G; Henze G; Niggli F; Ludwig WD; Janssen D; Riehm H; Schrappe M; Reiter A
    J Clin Oncol; 2006 Jan; 24(3):491-9. PubMed ID: 16421426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial.
    Horibe K; Yumura-Yagi K; Kudoh T; Nishimura S; Oda M; Yoshida M; Komada Y; Hara J; Tawa A; Usami I; Tanizawa A; Kato K; Kobayashi R; Matsuo K; Hori H;
    J Pediatr Hematol Oncol; 2017 Mar; 39(2):81-89. PubMed ID: 28169879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
    Qin Y; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang JL; Yang S; Zhang CG; Dong M; Zhou LQ; Wang JW; Feng FY; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):469-73. PubMed ID: 19950562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin.
    Todeschini G; Tecchio C; Meneghini V; Pizzolo G; Veneri D; Zanotti R; Ricetti MM; Solero P; April F; Perona G
    Leukemia; 1998 Feb; 12(2):144-9. PubMed ID: 9519775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Organ toxicity and efficacy of high-dose daunorubicin-based chemotherapy in the treatment of acute leukemia].
    Liu QG; Zhao X; Xu N; Wu LH; Li SZ; Mi YC
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):587-90. PubMed ID: 23906451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group.
    Matsuzaki A; Ishii E; Nagatoshi Y; Eguchi H; Koga H; Yanai F; Inada H; Nibu K; Tamai Y; Akiyoshi K; Nakayama H; Hara T; Take H; Miyazaki S; Okamura J
    Int J Hematol; 2001 Apr; 73(3):369-77. PubMed ID: 11345205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lim SN; Joo YD; Lee KH; Kim DY; Lee JH; Lee JH; Chi HS; Yun SC; Lee WS; Lee SM; Park S; Kim I; Sohn SK; Moon JH; Ryoo HM; Bae SH; Hyun MS; Kim MK; Kim HJ; Yang DH; Eom HS; Lee GW; Jung CW; Won JH; Kim H; Lee JH; Shin HJ; Jang DY
    Am J Hematol; 2015 Nov; 90(11):1013-20. PubMed ID: 26228525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment outcome of adult acute lymphocytic leukemia with VPD(L) regimen: analysis of prognostic factors.
    Park SR; Kim JH; Kim DY; Lee S; Lee SY; Choi IS; Yoon SS; Park S; Kim BG; Kim NK
    Korean J Intern Med; 2003 Mar; 18(1):21-8. PubMed ID: 12760264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.